Cancer Antigen (CA) 125 (Serial Monitor)
Also known as: CA-125 (Serial Monitor), CA125
Use
The Cancer Antigen (CA) 125 test is primarily used for long-term serial monitoring of individuals being treated for ovarian cancer. It measures the level of CA 125, a protein that is often elevated in the blood of some women with ovarian cancer. This test provides valuable information to clinicians by tracking changes in CA 125 levels over time to monitor the disease's progression or response to treatment. It is essential for adjusting therapeutic strategies based on elevation or reduction in CA 125 levels, thus aiding in assessing prognosis.
Special Instructions
Not provided.
Limitations
Values obtained with different assay methods cannot be used interchangeably in serial testing. Interpretation of test results must consider assay-specific reference intervals and should not be viewed as absolute evidence of the presence or absence of malignant disease. Biotin interference can lead to inaccurate results; hence patient supplement intake should be monitored. The test's completeness and reliability are limited by appropriate specimen collection, handling, and storage conditions.
Methodology
Immunoassay (ECLIA)
Biomarkers
Cancer Antigen (CA) 125
Analyte
LOINC Codes
- 10334-1 - Cancer Ag125 SerPl-aCnc
- 10334-1 - Cancer Ag125 SerPl-aCnc
- 80563-0 - Report
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.7 mL
Container
Gel-barrier tube (preferred) or red-top tube
Collection Instructions
If a red-top tube is used, transfer separated serum to a plastic transport tube.
Patient Preparation
Patients should be cautioned to stop biotin consumption at least 72 hours prior to the collection of a sample.
Storage Instructions
Room temperature
Other tests from different labs that may be relevant